Deal Description

Traction: 

1. We have developed Asia’s first & only gut microbiome & Vaginal microbiome tests for precision health 
2. We have invented & built a patentable world’s first translational science algorithm that decodes & analyses human biology at molecular level & translates it into actionable results to optimise human health.

Financials:

1. Average Monthly Revenue Run Rate = ₹ 1.20 Lakhs
2. Average Annual Revenue Run Rate = ₹ 14.50 Lakhs
3. EBITDA ~ 47% 
4. Gross Margin ~ 80% (backed by strong positive unit economics)

We have adopted a system biology approach to give a complete functional picture of health & disease of an individual that covers three technologies:

1. Whole genome sequencing to digitise biological data sets of an individual
2. Biological pathway analysis to decode molecular insights from sequencing step
3. Use Data Analytics/Machine Learning (Future) to derive precision actionable interventions from biological pathway analysis. 

Previous Investors:

1. Feb 2021 = Raised INR 2 Lakhs from Angel Investor at Pre Valuation of INR 1 Crore.
2. April 2021 = Secured INR 1 Lakh grant from the Ministry of Science & Technology, Govt. of India in IIM Udaipur Launch & Zoom 3.0 accelerator program.
3. January 2023 = Raised INR 25 Lakhs from Angel Investor at Pre Valuation of INR 7.5 Crore.

Looking to raise INR 1 Cr at valuation of INR 7.50 Cr.

Usage of Funds:

1. Tech Piece
2. Brand Building Initiatives
3. Developing Oral Microbiome Test
4. Human Genes Expression Tests
5. Opex
6. Man Power

No Files Attached